News

Avalyn Pharma's Upcoming Investor Conferences: Key Details

Avalyn Pharma's Upcoming Investor Conferences: Key Details

Avalyn Pharma's Upcoming Investor Conferences

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe pulmonary diseases, is gearing up for participation in multiple investor conferences this December. The leadership team is excited to engage with investors and share their vision for transforming treatment options for patients suffering from life-threatening respiratory conditions.

Key Conference Details

The two main conferences Avalyn will be attending this December are set to highlight important discussions surrounding healthcare advancements and innovations in the biopharmaceutical sector. Attendees can expect insightful presentations and discussions led by top executives from Avalyn.

7th Annual Evercore HealthCONx Conference

This prestigious conference will feature Avalyn's management team on December 3, at 3:50 p.m. ET. The format includes a fireside chat along with one-on-one meetings, providing a unique opportunity for investors to interact directly with the company's leaders.

Participants for Evercore Conference

The Evercore HealthCONx Conference will include Lyn Baranowski, CEO; Douglas Carlson, CFO, CBO; and Howard M. Lazarus, CMO of Avalyn. Their participation underlines the company's commitment to engaging with stakeholders and investors in the healthcare community.

Citi's 2024 Global Healthcare Conference

Following Evercore, Avalyn will continue their engagement at Citi's 2024 Global Healthcare Conference on December 4 at 11:00 a.m. ET. Similar to the previous conference, the format will consist of a fireside chat and exclusive one-on-one meetings to discuss the company's developments.

Participants for Citi's Conference

Once again, Lyn Baranowski, Douglas Carlson, and Howard M. Lazarus will represent Avalyn, providing insights into their innovative approaches in treating rare respiratory diseases.

About Avalyn Pharma

Avalyn Pharma is on the cutting edge of biopharmaceutical innovation, concentrating on inhaled therapies designed for rare respiratory diseases, such as pulmonary fibrosis and interstitial lung diseases (ILD). Pulmonary fibrosis not only deteriorates lung function but also significantly impacts patients' quality of life. Current treatment alternatives have limitations, including serious side effects that may deter their use.

Avalyn is working diligently to develop advanced inhaled formulations that aim to directly target the lungs while minimizing systemic exposure. Their foremost program, designated as AP01, constitutes an optimized inhaled formulation of pirfenidone and is currently being explored in the MIST Phase 2b Study for progressive pulmonary fibrosis. So far, AP01 has been tested in over 150 individuals, showcasing impressive clinical proof-of-concept and yielding better safety and efficacy results compared to existing treatments.

Future Developments

In addition to AP01, Avalyn is progressing toward initiating a Phase 1b study for its second program, labeled AP02, which features inhaled nintedanib aimed at addressing idiopathic pulmonary fibrosis (IPF). Such innovative initiatives mark Avalyn as a forward-thinking participant in the biopharmaceutical landscape.

Contact Information

Investor Contact:
Alex Straus
THRUST Strategic Communications
alex@thrustsc.com
ir@avalynpharma.com

Media Contact:
Marites Coulter
Deerfield Group
marites.coulter@deerfieldgroup.com
media@avalynpharma.com

Frequently Asked Questions

What is Avalyn Pharma known for?

Avalyn Pharma specializes in developing inhaled therapies for treating severe pulmonary diseases like pulmonary fibrosis.

What conferences will Avalyn Pharma participate in?

Avalyn Pharma will participate in the Evercore HealthCONx Conference and Citi's 2024 Global Healthcare Conference in December.

Who are the key participants from Avalyn Pharma at the conferences?

The key participants include Lyn Baranowski (CEO), Douglas Carlson (CFO, CBO), and Howard M. Lazarus (CMO).

What is AP01?

AP01 is Avalyn's lead program, an optimized inhaled formulation of pirfenidone, currently undergoing trials for progressive pulmonary fibrosis.

How can I contact Avalyn Pharma?

You can contact Avalyn Pharma through their investor relations email at ir@avalynpharma.com or their media contact at media@avalynpharma.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Backdoor Reference Checks: A Hiring Minefield?

Updated Category News Views 132

What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...

Continue Reading
WhiteHorse Set to Redeem Its 2028 Notes Completely

Updated Category News Views 98

WhiteHorse Finance Divests Its 7.875% Notes Well, WhiteHorse Finance is making some moves, folks. They're planning to redeem their 7.875% notes due in 2028, totaling a cool $34.5 million. This ain't just pocket change, especially with the way markets have been bobbing and weaving lately. The redemption is slated for December 15, 2026, when the notes will get delisted from...

Continue Reading
Missoula Inventor Offers Handy Phone Solution on the Move

Updated Category News Views 83

Adjustable Convenience for the Modern Commuter When you're commuting or just lounging around, less hand strain and more comfort sounds like a no-brainer, right? Well, an inventive soul from Missoula, Montana, just might have cracked this little nut with a gizmo they're calling the COMMUTER PHONE. Imagine never having to juggle your phone during those bumpy moments on the...

Continue Reading
Pine AI Unveils AI Studio & Real-World Call Feature

Updated Category News Views 208

Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...

Continue Reading
CVRx Faces Legal Storm: Investors Grapple with Fallout

Updated Category News Views 150

CVRx in the Crosshairs: Legal and Operational Woes There's a storm brewing over at CVRx, Inc. (NASDAQ: CVRX), and it's pulling investors down a hell of a financial rabbit hole. You might think you're in the clear with a company like CVRx that boasts approved devices, but think again. Recent revelations have shown that even those with FDA stamps aren't immune to the...

Continue Reading
Thanksgiving in Outer Banks: Unique Traditions Await

Updated Category News Views 78

Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...

Continue Reading
Innovative Rotating Kitchen Organizer Up for Licensing

Updated Category News Views 87

Dusting Off the Corners: A Fresh Spin on Kitchen Storage Just when you think there's nothing new under the sun when it comes to storing your kitchen gadgets, here comes an invention straight out of Billings, Montana. It's called The Rotating Kitchen Organizer, a nifty contraption that's all set to turn those dead corners into prime real estate. How many times have we...

Continue Reading
Custom Upholstered Furniture: Comfort Built to Last

Updated Category News Views 115

Rethinking Furniture Comfort: Not Just a Luxury Diving into the world of custom upholstered furniture with insights from Randy Marohn is like finding a cheat sheet for comfort. Seriously, it ain't just about plush cushions or slick fabrics—it's a bonafide science. Marohn, from Sans Furniture Inc. in good ol’ Hamburg, NY, unfolds a tale of intentional design and...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 136

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
When to Switch Your LLC to S Corp Status: Tips

Updated Category News Views 61

Is Your LLC Ready for the S Corp Leap? Thinking about shifting your LLC to S corporation status? You're not alone—many business owners hit this fork in the road as their enterprise starts rolling in more dough. And if you're scratching your head wondering if this switch makes sense for your venture, listen up because timing and context are everything here. When Should...

Continue Reading

Top 5 Most Recently Viewed Articles

Gluware Secures Strategic Investment to Propel Growth in Automation

Updated Category News Views 246

Gluware Strengthens Position in Network Automation Market In a significant move to enhance its market position, Gluware has announced a strategic partnership with Cuadrilla Capital, a prominent private equity firm specializing in enterprise software. This collaboration is designed to accelerate Gluware's growth trajectory, focusing on catering to the Global 2000 market...

Continue Reading
Aspo Plc's Q3 2024 Interim Report Release and Key Details

Updated Category News Views 91

Aspo Plc Announces Interim Report for Q3 2024 Aspo Plc is set to unveil its interim report for the period of January through September 2024 on a scheduled date. This release is an important milestone for the company as it aims to provide updated insights on its financial performance and strategic positioning. Key Meeting Details The report will be officially published on...

Continue Reading
Noridian Welcomes New Director to Enhance Data Strategy

Updated Category News Views 155

Noridian Appoints Jill Baber as Director of Enterprise Data Noridian Healthcare Solutions, LLC has made a pivotal decision to enhance its data strategy with the appointment of Jill Baber as its new director of Enterprise Data. This strategic move is geared towards improving data-driven decision-making and fostering improved collaboration within the organization. Jill...

Continue Reading
RSUPPORT Achieves Prestigious ISO Certifications for Security

Updated Category News Views 113

RSUPPORT Validates Top-Tier Security with ISO/IEC Certifications Asia's No.1 Remote Solutions Provider Once Again Recognized for Outstanding Security Excellence RSUPPORT Co., Ltd., a leading provider of remote solutions, has proudly announced that its Global Research and Development Center received two prestigious certifications in information security: ISO/IEC 27001:2022...

Continue Reading
Market Dynamics Shaped by Earnings and Tariffs Affecting Trading

Updated Category News Views 217

Asian Market Wrap As Asian stock markets experienced slight dips after reaching a four-year high, investors are keenly watching upcoming corporate earnings amidst ongoing tariff discussions. The MSCI Asia-Pacific index, excluding Japan, reached its highest value since October 2021 before retracting by 0.4%. Notably, this index has surged nearly 16% this year. After...

Continue Reading